The efficacy and tolerability of Tazarotene foam, 0.1%, in the treatment of acne vulgaris in 2 multicenter, randomized, vehicle-controlled, double-blind studies

Journal of Drugs in Dermatology

Volumn 12, Issue 4, 2013, Pages 438-446

  Feldman, Steven R ^a   Werner, Cary P ^b   Saenz, Alessandra B Alió ^b  

^a WAKE FOREST UNIVERSITY HEALTH SCIENCES   (United States)

^b Stiefel Laboratories Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

TAZAROTENE;

ACNE VULGARIS; ADOLESCENT; ADULT; APPLICATION SITE DERMATITIS; APPLICATION SITE DRYNESS; APPLICATION SITE ERYTHEMA; APPLICATION SITE EXFOLIATION; APPLICATION SITE IRRITATION; APPLICATION SITE PAIN; APPLICATION SITE PHOTOSENSITIVITY REACTION; APPLICATION SITE PRURITUS; APPLICATION SITE REACTION; ARTICLE; BRAIN CONTUSION; CHILD; CLINICAL ASSESSMENT; CONTROLLED STUDY; DEPRESSION; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG FORMULATION; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEMALE; HUMAN; INFLAMMATION; INVESTIGATOR STATIC GLOBAL ASSESSMENT; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; RANDOMIZED CONTROLLED TRIAL; SCHOOL CHILD; SCORING SYSTEM; SUBJECT GLOBAL ASSESSMENT; TREATMENT OUTCOME;

ACNE VULGARIS; ADMINISTRATION, CUTANEOUS; ADOLESCENT; ADULT; CANADA; CHILD; DERMATOLOGIC AGENTS; DOUBLE-BLIND METHOD; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; NICOTINIC ACIDS; SEVERITY OF ILLNESS INDEX; UNITED STATES; YOUNG ADULT;

EID: 84875854452     PISSN: 15459616     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (21)

1. Millikan LE. The rationale for using a topical retinoid for inflammatory acne. Am J Clin Dermatol. 2003;4:75-80. (Pubitemid 36259516)
2. Jeremy AH, Holland DB, Roberts SG, et al. Inflammatory events are involved in acne lesion initiation. J Invest Dermatol. 2003;121:20-27. (Pubitemid 36900450)
3. Do TT, Zarkhin S, Orringer JS, et al. Computer-assisted alignment and tracking of acne lesions indicate that most inflammatory lesions arise from comedones and de novo. J Am Acad Dermatol. 2008;58:603-608.
4. Rosen T. The Propionibacterium acnes genome: from the laboratory to the clinic. J Drugs Dermatol. 2007;6:582-586.
5. Talpur R, Cox K, Duvic M. Efficacy and safety of topical tazarotene: a review. Expert Opin Drug Metab Toxicol. 2009;5:195-210.
6. Thiboutot D, Gollnick H, Bettoli V, et al. New insights into the management of acne: an update from the Global Alliance to Improve Outcomes in Acne group. J Am Acad Dermatol. 2009;60:S1-S50.
7. Draelos ZD, Tanghetti EA. Optimizing the use of tazarotene for the treatment of facial acne vulgaris through combination therapy. Cutis. 2002;69:20-29.
8. Shalita AR, Berson DS, Thiboutot DM, Leyden JJ, Parizadeh D, Sefton J, et al. Effects of tazarotene 0.1 % cream in the treatment of facial acne vulgaris: pooled results from two multicenter, double-blind, randomized, vehicle-controlled, parallel-group trials. Clin Ther 2004;26:1865-1873 (Pubitemid 40089499)
9. Shalita AR, Chalker DK, Griffith RF, et al. Tazarotene gel is safe and effective in the treatment of acne vulgaris: a multicenter, double-blind, vehicle-controlled study. Cutis. 1999;63:349-354.
10. Tanghetti E, Dhawan S, Green L, et al. Randomized comparison of the safety and efficacy of tazarotene 0.1% cream and adapalene 0.3% gel in the treatment of patients with at least moderate facial acne vulgaris. J Drugs Dermatol. 2010;9:549-558.
11. Fabior™ (tazarotene Foam, 0.1%) [package insert]. Research Triangle Park, NC: Stiefel Laboratories, Inmce; 2012.
12. Zhao Y, Jones SA, Brown MB. Dynamic foams in topical drug delivery. J Pharm Pharmacol. 2010;62:678-684.
13. Feldman SR, Sangha N, Setaluri V. Topical corticosteroid in foam vehicle offers comparable coverage compared with traditional vehicles. J Am Acad Dermatol. 2000;42:1017-1020. (Pubitemid 30368671)
14. Gupta AK, Gover MD, Abramovits W. EVOCLIN (clindamycin phosphate foam, 1%). Skinmed. 2005;4:96-97
15. Del Rosso JQ. Truncal acne vulgaris: the relative roles of topical and systemic antibiotic therapy. J Drugs Dermatol. 2007;6:148-151
16. Tamarkin D, Friedman D, Shemer A. Emollient foam in topical drug delivery. Expert Opin Drug Deliv. 2006;3:799-807 (Pubitemid 44781851)
17. Housman TS, Mellen BG, Rapp SR, et al. Patients with psoriasis prefer solution and foam vehicles: a quantitative assessment of vehicle preference. Cutis. 2002;70:327-332. (Pubitemid 41757440)
18. Gottlieb AB, Ford RO, Spellman MC. The efficacy and tolerability of clobetasol propionate foam 0.05% in the treatment of mild to moderate plaque-type psoriasis of nonscalp regions. J Cutan Med Surg. 2003;7:185-192 (Pubitemid 36859094)
19. Feldman S, Wyres M, Markowitz O, et al. Calcipotriene foam for the treatment of plaque-type psoriasis: Results of two phase III studies [abstract P3361]. J Am Acad Dermatol. 2010;62:3 (Suppl 1):AB138.
20. Cash K, Quigley MO. The vehicle found in ketoconazole foam 2% is preferred by patients with mild to severe seborrheic dermatitis over other vehicles, regardless of gender, age, or ethnicity. J Am Acad Dermatol. 2008;58:AB92
21. Leyden J, Grove G, Zerweck C. Facial tolerability of topical retinoid therapy. J Drugs Dermatol. 2004;3:641-651